UroGen Pharma (NASDAQ:URGN - Get Free Report) released its earnings results on Monday. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09), Zacks reports.
UroGen Pharma Trading Down 3.0%
Shares of URGN stock opened at $10.35 on Monday. The firm's fifty day simple moving average is $10.64 and its 200 day simple moving average is $10.97. UroGen Pharma has a 1 year low of $8.94 and a 1 year high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The firm has a market capitalization of $477.21 million, a P/E ratio of -3.29 and a beta of 0.66.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a "buy" rating and issued a $55.00 target price on shares of UroGen Pharma in a research report on Monday, April 28th. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Thursday. Guggenheim reaffirmed a "buy" rating on shares of UroGen Pharma in a research note on Tuesday, April 29th. The Goldman Sachs Group decreased their price target on UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Finally, LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $32.86.
View Our Latest Research Report on URGN
UroGen Pharma Company Profile
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
